Free shipping on all orders over $ 500

 About 5 results found for searched term "Gefitinib" (0.054 seconds)

Cat.No.  Name Target
M1749 Gefitinib EGFR/HER2
ZD-1839, Iressa
Gefitinib (ZD1839) is an EGFR tyrosine kinase and Akt phosphorylation inhibitor. Gefitinib significantly down-regulates CD47 expression and increases DC phagocytosis in non-small cell lung cancer cells such as PC9, H1437 and H1573. Gefitinib combined with CD47 antibody can enhance the phagocytosis of macrophages.
M5679 Gefitinib HCl EGFR/HER2
ZD-1839 hydrochloride
Gefitinib Hcl(ZD-1839 Hcl) is an EGFR inhibitor, which interrupts signaling through the epidermal growth factor receptor (EGFR) in target cells. Therefore, it is only effective in cancers with mutated and overactive EGFR.
M14871 Gefitinib-based PROTAC 3 PROTAC
Gefitinib-based PROTAC 3, conjugating an EGFR binding element to a von Hippel-Lindau ligand via a linker, induces EGFR degradation with DC50s of 11.7 nM and 22.3 nM in HCC827(exon 19 del) and H3255 (L858R mutantion) cells, respectively.
M39071 Gefitinib impurity 1 Metabolite/Endogenous Metabolite
Gefitinib impurity 1 is the impurity of Gefitinib. Gefitinib (ZD1839) is a potent, selective and orally active EGFR tyrosine kinase inhibitor with an IC50 of 33 nM. Gefitinib selectively inhibits EGF-stimulated tumor cell growth (IC50 of 54 nM).
M42084 Gefitinib N-oxide hydrochloride EGFR/HER2
Gefitinib N-oxide hydrochloride is the N-oxide derivative of Gefitinib.



Products are for research use only. Not for human use. We do not sell to patients.
© Copyright 2010-2023 AbMole BioScience. All Rights Reserved.